Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biotherapy in clinical practice.

R A Figlin1

  • 1Department of Medicine, UCLA School of Medicine.

Seminars in Hematology
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

Interferons, a class of biologic response modifiers, show clinical activity against various cancers. However, antibody formation against recombinant interferons may reduce treatment effectiveness, necessitating standardized trials to resolve this controversy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.

British journal of cancer·2017
Same author

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

European journal of cancer (Oxford, England : 1990)·2014
Same author

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

British journal of cancer·2014
Same author

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.

British journal of cancer·2012
Same author

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.

British journal of cancer·2012
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Interferons are a novel class of biologic response modifiers.
  • They have demonstrated significant clinical efficacy in treating hematologic malignancies, lymphomas, and solid tumors.

Purpose of the Study:

  • To review the clinical activity of interferons in various cancers.
  • To discuss the implications of antibody formation against recombinant interferons.
  • To highlight the need for standardized trials to clarify the role of antibodies in treatment efficacy.

Main Methods:

  • Review of existing clinical data on interferon therapy.
  • Analysis of studies investigating antibody formation in patients treated with interferons.
  • Discussion of factors influencing treatment response and antibody development.

Related Experiment Videos

Main Results:

  • Interferons are effective against specific cancers like hairy-cell leukemia, chronic myelogenous leukemia, and malignant melanoma.
  • Recombinant interferons can elicit an immune response, leading to antibody formation.
  • Antibodies against interferons have been linked to reduced clinical responsiveness in some patients.

Conclusions:

  • Interferons represent a valuable therapeutic option in oncology.
  • The potential for antibody formation necessitates careful monitoring and further research.
  • Standardized prospective trials are crucial to definitively assess the impact of antibodies on interferon treatment outcomes.